RT @TrlsChangeLives: #CochraneDaily BOLT study ran into Cochrane with several entries in CENTRAL and included in @CochraneLibrary review ht…
#CochraneDaily BOLT study ran into Cochrane with several entries in CENTRAL and included in @CochraneLibrary review https://t.co/TQzbQgVqL9
Updated #CochraneEyes review: Do patients benefit from anti-VEGFs for diabetic macular oedema (#DMO)? http://t.co/Pkb8ll7WOK
Updated #CochraneEyes review: Do patients benefit from anti-VEGFs for diabetic macular oedema (#DMO)? http://t.co/Pkb8ll7WOK
Updated #CochraneEyes review: Do patients benefit from anti-VEGFs for diabetic macular oedema (#DMO)? http://t.co/Pkb8ll7WOK
MT @tlassers: Antiangiogenic drugs. #Diabetic macular oedema. Large, consistent effects. #CochraneEvidence http://t.co/nlGdnBh3ml
(Cochrane) El tto antiangiogénico es más eficaz que el habitual en el edema macular diabético http://t.co/d8tVcqyoGY
MT @tlassers: Antiangiogenic drugs. #Diabetic macular oedema. Large, consistent effects. #CochraneEvidence http://t.co/nlGdnBh3ml
Antiangiogenic therapy for diabetic macular oedema http://t.co/4K6jZwmOSO
Antiangiogenic drugs. Diabetic macular oedema. Large, consistent effects. #CochraneEvidence http://t.co/FpMjuN7qX0